Tag Archives: Avandia
Leading doctor tells Congress to pull Avandia and halt study
Leading public health advocate Dr. Sidney Wolfe, of Public Citizen, told a House subcommittee, on April 28, that the FDA should stop an Avandia study and remove the diabetes drug from the market. Dr. Wolfe said the study is keeping … Continue reading
California county files Avandia class action against GSK
A California county has filed a class action lawsuit against Avandia-maker GlaxoSmithKline (GSK), claiming GSK hid evidence that Avandia increases the risk of heart attacks. County officials in Santa Clara County, in northern California, say they believe this is the … Continue reading
Dr. Steven Nissen affirms Avandia risks
The doctor that helped focus scientific scrutiny on the heart dangers of Avandia says the diabetes drug remains controversial. “Many physicians have stopped prescribing Avandia,” Dr. Nissen said. Dr. Nissen points out, in a recent US News column, that the … Continue reading
American Heart Association’s Defense of Avandia (Questionable Motives)
The always provocative blogger, Jim Edwards, who has historically printed some extremely insightful columns on the pharmaceutical industry, is at it again. This time, the motivations behind the American Heart Association’s suggestion that recent reports and findings that Avandia (Rosiglitazone) … Continue reading
Drug marketing expert says GSK uses scorched-earth corporate culture to hide Avandia dangers
The maker of diabetes drug Avanida, GlaxoSmithKline (GSK), has a “scorched-earth corporate culture” and uses marketing and advertising to hide known dangers of its multi-billion dollar drug, according to Jim Edwards, a former managing editor of Adweek. Edwards’ scathing editorial … Continue reading
Secret tapes of Avandia-maker meeting reveal deceptions
Secret tapes of a meeting between GlaxoSmithKline (GSK) executives and a prominent medical researcher reveal deceptive tactics by the company, according to a Feb. 22 New York Times article detailing the recordings, which were never previously disclosed. In 2007, GSK … Continue reading
Avandia drags down GSK stock and the UK FTSE 100
The Financial Times is reporting that the recent Senate committee report on the dangers of Avandia is pushing down the value of Avandia manufacturer GlaxoSmithKline (GSK). “The FTSE 100 broke a five-day winning streak yesterday with GlaxoSmithKline solely responsible for … Continue reading
FDA doctors say Avandia “should be removed from the market”
Two FDA epidemiologists have said the diabetes drug Avandia (rosiglitazone) should be pulled from the market due to increased risk of heart failure and heart attacks. David Graham, MD, and Kate Gelperin, MD, both epidemiologists with the FDA, where quoted … Continue reading
Avandia maker hid dangers from public for years, says Senate report
“GSK had a duty to sufficiently warn patients and the FDA of its concerns in a timely manner. Instead, GSK executives intimidated independent physicians, focused on strategies to minimize findings that Avandia may increase cardiovascular risk, and sought ways to downplay findings that the rival drug ACTOS (pioglitazone) might reduce cardiovascular risk.” — Baucus/Grassley letter to FDA Continue reading
Avandia Implicated as Causing Liver Damage
Aylstock, Witkin, Kreis & Overholtz is one of the lead plaintiffs’ firms in the country pursuing the national litigation effort against GlaxoSmithKline relating to its diabetes drug Avandia (rosiglitazone). The adverse events and injuries which have been associated with Avandia … Continue reading